Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: BIONEX "The Holy Grail" of blood treatment

No earlier versions found for this Subject.

Return to BIONEX "The Holy Grail" of blood treatment

The BIONEX compound "The Holy Grail for Blood Treatment"

Discussions about the blood contamination around the world and what methods are used to prevent the
transmission of deadly diseases.

Many conventional methods have been used to date to clean the blood supply. But is it enough?

There is a new compound called the BIONEX. Altachem Pharma Ltd owns the world wide rights to its
patents and is working on its research, its development and its distribution on the market.

The potential market for blood treatment is over 10 billion dollars a year that is the estimate from
CERUS corporation that has a possible compound still in research (NASDAQ: CERS).

Other related websites:

altachempharma.com

stockhouse.com.

Subject 36747

Subject 36755